Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
FDA Approves Pembrolizumab Regimen for Platinum-Resistant Ovarian Cancer
The FDA approved pembrolizumab, including the Qlex formulation, with paclitaxel with or without bevacizumab for certain PD-L1-positive ovarian, fallopian tube or primary peritoneal cancers.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA approved pembrolizumab and pembrolizumab with berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, on 10 February.
The indication covers adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express PD-L1 with CPS at least 1 and who have received one or two prior systemic treatment regimens.
Platinum-resistant ovarian cancer is difficult to treat, so regulatory changes in this setting are closely watched even when the benefit applies to a biomarker-defined subgroup.
Sourcing note: Indication language is from FDA. This article does not compare the regimen against individual patient alternatives or provide treatment advice.
Why It Matters
The approval expands immunotherapy-based options in a disease setting where recurrence after platinum therapy leaves limited choices. The PD-L1 test requirement also reinforces how ovarian cancer treatment is becoming more biomarker-specific.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAPembrolizumabOvarian CancerOncologyPlatinum-Resistant Disease